著者
Takeshi Yagyu Satoshi Yasuda Noritoshi Nagaya Kaori Doi Takeshi Nakatani Kazuhiro Satomi Wataru Shimizu Kengo Kusano Toshihisa Anzai Teruo Noguchi Hajime Ohgushi Soichiro Kitamura Kenji Kangawa Hisao Ogawa
出版者
The Japanese Circulation Society
雑誌
Circulation Journal (ISSN:13469843)
巻号頁・発行日
pp.CJ-18-1179, (Released:2019-05-17)
参考文献数
45
被引用文献数
11

Background:Mesenchymal stem cells (MSCs), which have the potential to differentiate into cardiomyocytes or vascular endothelial cells, have been used clinically as therapy for cardiomyopathy. In this study, we aimed to evaluate the long-term follow-up results.Methods and Results:We studied 8 patients with symptomatic heart failure (HF) on guideline-directed therapy (ischemic cardiomyopathy, n=3; nonischemic cardiomyopathy, n=5) who underwent intracardiac MSC transplantation using a catheter-based injection method between May 2004 and April 2006. Major adverse events and hospitalizations were investigated up to 10 years afterward. Compared with baseline, there were no significant differences in B-type natriuretic peptide (BNP) (from 211 to 173 pg/mL), left ventricular ejection fraction (LVEF) (from 24% to 26%), and peak oxygen uptake (from 16.5 to 19.2 mL/min/kg) at 2 months. During the follow-up period, no patients experienced serious adverse events such as arrhythmias. Three patients died of pneumonia in the 1st year, liver cancer in the 6th year, and HF in the 7th year. Of the remaining 5 patients, 3 patients were hospitalized for exacerbated HF, 1 of whom required heart transplantation in the 2nd year; 2 patients survived for 10 years without worsening HF.Conclusions:The results of this exploratory study of intracardiac MSCs administration suggest further research regarding the feasibility and efficacy is warranted.
著者
Soichiro Kitamura Takeshi Nakatani Tomoko Kato Masanobu Yanase Junjiro Kobayashi Hiroyuki Nakajima Toshihiro Funatsu Koichi Toda Akiko Kada Hitoshi Ogino Toshikatsu Yagihara
出版者
The Japanese Circulation Society
雑誌
Circulation Journal (ISSN:13469843)
巻号頁・発行日
vol.73, no.7, pp.1235-1239, 2009 (Released:2009-06-25)
参考文献数
22
被引用文献数
14 19

Background: The purpose of this study was to evaluate the hemodynamic and echocardiographic function of hearts transplanted with the modified bicaval anastomosis technique (mBCAT). Methods and Results: Twenty consecutive patients (14 males, 6 females, age range 14-61 [41.3 ±11.5 years]) were evaluated 3.4 ±2.2 years after heart transplantation using the mBCAT. All patients were in status I on the waiting list, and 18 (90%) had had a left ventricular assist device. The donor age was 39 ±12 years. Triple immunosuppressive regimen and cardiac biopsy were routinely performed. There was no hospital mortality. One death occurred 4.2 years after the operation because of bone marrow dysplasia and infection. The 8-year survival was 89% (95%confidence interval: 0.43-0.98). All the hemodynamic variables returned to the normal range. Low right atrial pressure (3.2 ±1.5 mmHg) and low pulmonary wedge pressure (6.7 ±2.1 mmHg) were associated with an excellent cardiac index (3.9 ±0.7 L · min-1 · m-2). Echocardiography revealed an excellent late peak velocity (52 ±19 cm/s) and an E/A ratio (1.4 ±0.6) of tricuspid flow. The grade (0-4) of tricuspid regurgitation averaged 1.5 ±0.8. Conclusions: Hemodynamic and echocardiographic results for mBCAT were excellent. The 8-year survival was 89% with all surviving patients in New York Heart Association class I. The mBCAT is easy to perform and further facilitates cardiac transplantation. (Circ J 2009; 73: 1235-1239)
著者
Noboru Oda Tomoko S. Kato Akihisa Hanatani Kazuo Niwaya Takeshi Nakatani Hatsue Ishibashi-Ueda Soichiro Kitamura Kazuhiko Hashimura Masafumi Kitakaze Kazuo Komamura
出版者
The Japanese Society of Internal Medicine
雑誌
Internal Medicine (ISSN:09182918)
巻号頁・発行日
vol.49, no.11, pp.1013-1016, 2010 (Released:2010-06-01)
参考文献数
15
被引用文献数
7 10

Reversible posterior leukoencephalopathy syndrome (RPLS) is one of the important adverse events following organ transplantation, associated with calcineurin inhibitors (CNIs). We describe a case of 54-year-old woman, who was diagnosed with RPLS within weeks after transplantation. Considering the risk of causing fatal rejection by discontinuation of CNIs, the immunosuppressive regimen of the patient was switched from a cyclosporine A-based regimen to a tacrolimus-based regimen. The patient recovered rapidly from RPLS following the switch to tacrolimus. This case demonstrated that not only discontinuation but also a substitution of CNIs would be a valid treatment option for RPLS in transplant recipients.